Product Details
| Product Name:
TOFA |
CAS No.:
54857-86-2 |
| Purity:
99.77% |
Supply Ability:
10g |
| Release date:
2026/05/11 |
Product Introduction
Bioactivity
| Name | TOFA |
| Description | TOFA (MDL14514) is an allosteric inhibitor of acetyl-CoA carboxylase-α (ACCA). |
| Cell Research | NCI-H460, human lung cancer cells, and HCT-8 and HCT-15 cells (5,000/well) are seeded in 96-well plates overnight and then exposed to TOFA at indicated concentrations (0, 1, 5, 10, 20, 50 μg/mL) for 72 hours. Viable cells are detected using MTT assay[1]. |
| In vitro | TOFA (5-tetradecyloxy-2-furoic acid) inhibits cancer cell proliferation by inducing apoptosis, arresting cells in the G0/G1 phase, and showing time and dose-dependent cytotoxic effects. It targets Acetyl-CoA-carboxylase-α (ACCA), leading to reduced fatty acid synthesis, caspase activation, and cell death, particularly in prostate cancer (PCa) cells. TOFA exhibits significant cytotoxicity in lung cancer cells NCI-H460 and colon carcinoma cells HCT-8 and HCT-15, with IC50 values of around 5.0, 5.0, and 4.5 μg/mL, respectively. Concentrations from 1.0 to 20.0 μg/mL block fatty acid synthesis and induce cell death dose-dependently. It is also cytotoxic to COC1 and COC1/DDP cells, with IC50 values of approximately 26.1 and 11.6 μg/mL, respectively. |
| In vivo | The tumor growth rate is signifi?cantly inhibited by TOFA compared with the DMSO treated control mice (1649±356.3 vs. 5128±390.4 mm3. No toxicity is observed in the heart, liver, spleen, lung, kidney and intestinal tissues. TOFA inhibits COC1/DDP cell growth in ovarian tumor mouse xenografts. By inhibiting ACC, TOFA may be a promising small molecule agent for ovarian cancer therapy. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 12.38 mg/mL (38.16 mM), Sonication is recommended.
|
| Keywords | TOFA | RMI-14514 | RMI 14514 | MDL-14514 | MDL 14514 | Inhibitor | inhibit | AcetylCoACarboxylase | Acetyl-CoA Carboxylase | AcetylCoA Carboxylase | ACC1 | ACC, Acetyl Coenzyme A Carboxylase | ACC |
| Inhibitors Related | Alisol A | CMS-121 | Cyhalofop-butyl | Acetyl-CoA Carboxylase-IN-1 | Firsocostat | PF-05221304 | Clethodim | Moiramide B | Clodinafop-propargyl | VY-3-135 | Quizalofop-ethyl | Tralkoxydim |
| Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | Anti-Obesity Compound Library | Anti-Viral Compound Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library | NO PAINS Compound Library | Lipid Metabolism Compound Library | Bioactive Compounds Library Max | Anti-Metabolism Disease Compound Library | Anti-COVID-19 Compound Library | Anti-Hypertension Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$6.60
|
VIP7Y
|
Career Henan Chemical Co
|
2020-01-03 |
United States